Search results
Results From The WOW.Com Content Network
Eplerenone is an antimineralocorticoid, or an antagonist of the mineralocorticoid receptor (MR). [21] Eplerenone is also known chemically as 9,11α-epoxy-7α-methoxycarbonyl-3-oxo-17α-pregn-4-ene-21,17-carbolactone and "was derived from spironolactone by the introduction of a 9α,11α-epoxy bridge and by substitution of the 17α-thoacetyl ...
Eplerenone is a newer drug that was developed as a spironolactone analog with reduced adverse effects. In addition to the y-lactone ring and the substituent on C-7, eplerenone has a 9α,11α-epoxy group. This group is believed to be the reason why eplerenone has a 20-40-fold lower affinity for the mineralocorticoid receptor than spironolactone. [7]
Tractive develops and sells GPS & Health trackers for dogs and cats that enable pet owners to view their pet's real-time location, receive Health Alerts, and monitor activity and sleep patterns via a smartphone app. Tractive tracks around 1,000,000 pets in over 175 countries worldwide using GPS and GSM technology.
With a 355° pan range, AI detection, and customizable alarm sound, this pet cam has a lot of impressive features.View Deal. DeWillems explains that it can be helpful to know what your dog is ...
Potassium-sparing diuretics act to prevent sodium reabsorption in the collecting tubule by either binding ENaCs (amiloride, triamterene) or by inhibiting aldosterone receptors (spironolactone, eplerenone). This prevents excessive excretion of K + in urine and decreased retention of water, preventing hypokalemia. [10]
How MADACC's five-day test drive program works. The Sign and Foster Test Drive program soft-launched on May 1. Originally, only dogs over 40 pounds could be test-drive fosters.
Three teens face charges after a Marta bus driver, identified as Leroy Ramos, was killed, officials say.
Esaxerenone (INN Tooltip International Nonproprietary Name) (brand name Minnebro; developmental code names CS-3150, XL-550) is a nonsteroidal antimineralocorticoid which was discovered by Exelixis and developed by Daiichi Sankyo Company and is approved in Japan for the treatment of hypertension.